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Resumo 
Para o tratamento da dor crónica, uma condição multifatorial, é necessário um diagnóstico 
adequado que permita a diferenciação da dor nas suas diversas componentes. A neuropatia 
diabética está presente em todo o mundo e tem um grande impacto na sociedade atual. A 
diabetes poderá desencadear a produção de espécies reativas de oxigénio, associadas ao 
stress oxidativo, que poderão ser um fator-chave no desenvolvimento da neuropatia. 
O objetivo principal deste trabalho é averiguar uma eventual associação entre dor crónica, 
neuropatia diabética e stress oxidativo. 
Neste sentido, foi desenvolvida uma meta-análise, que permitiu a avaliação da relação causal 
entre o stress oxidativo e a neuropatia diabética, e, também, a aplicação de questionários 
validados para a avaliação da dor, o Brief Pain Inventory (BPI) e o Douleur Neuropathique 
4 (DN4) a uma amostra de conveniência. 
Na meta-análise avaliaram-se resultados para indicadores de stress oxidativo, como a 
peroxidação lipídica, as atividades da superóxido dismutase e da catalase, e, ainda, a 
glutationa reduzida. Selecionaram-se, de entre 257 artigos, 9 estudos realizados em ratinhos 
diabéticos neuropáticos e em controlos saudáveis. Os níveis de peroxidação lipídica estão 
elevados em todos os estudos, enquanto os níveis dos restantes biomarcadores se encontram 
diminuídos, comparando o grupo diabético com o grupo controlo. 
Na avaliação da amostra de conveniência, foram recolhidos 84 inquéritos ao longo das 
quatro estações: verão, outono, inverno e primavera. As queixas de dor foram descritas em 
termos do local e intensidade, do alívio da dor com toma de medicação e os efeitos da dor 
nas atividades diárias, através do BPI. Os scores obtidos no BPI indicam a presença de dor 
moderada a severa, aumentada no outono e na primavera, com implicações nas tarefas 
diárias, e transversais aos grupos estudados. Para determinar as principais caraterísticas 
associadas à dor neuropática, utilizou-se o DN4. Este indicou a presença de cerca de 50% de 
doentes com dor neuropática. Os resultados sugerem, ainda, que ser mulher, o aumento da 
idade e estar em situação de inatividade profissional são fatores que podem influenciar a dor 
crónica e, consequentemente, a dor neuropática.  
Os resultados obtidos neste estudo apontam para uma possível existência de uma associação 
entre stress oxidativo e dor neuropática, e, ainda, uma possível ligação entre as condições 
climáticas e queixas/prevalência de dor. 
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Abstract  
For treating chronic pain, a multifactorial condition, is needed a suitable diagnosis which 
allows the differentiation in its many components. Diabetic neuropathy is a worldwide 
disease with great impact in the modern society. Diabetes may leads to the production of 
reactive oxygen species that are associated to oxidative stress, which may be a key factor in 
the development of diabetic neuropathy.  
The main goal is to inquire a potential association between chronic pain, diabetic neuropathy 
and oxidative stress. 
Thus, was performed a meta-analysis that permitted the causal evaluation between oxidative 
stress and diabetic neuropathy, and, a pain evaluation was accomplished in a convenience 
sample using validated surveys – Brief Pain Inventory (BPI) and Douleur Neuropathique 4 
(DN4). 
Through the meta-analysis it was possible evaluate oxidative stress biomarkers, such lipid 
peroxidation, superoxide dismutase and catalase activities, and reduced glutathione. 9 
studies were selected and all were performed in mouse models. The levels of lipid 
peroxidation were increased in all the studies, however the levels of the other biomarkers 
were diminished in diabetic models comparatively to healthy controls.  
In the evaluation of convenience sample, 84 surveys were collected along the four seasons: 
summer, autumn, winter and spring. The pain complaints were described in terms of local, 
intensity, impact, relief by medication and its effect on daily activities using BPI 
questionnaire. The scores obtained in BPI indicate the presence of moderate to severe pain, 
with increased complaints in autumn and spring, and implications in daily activities, 
transversal to all groups. To determine the main features associated with neuropathic pain it 
was used DN4 questionnaire. The DN4 indicated the presence of nearly 50% of patients with 
neuropathic pain. The results suggest that being female, the increased age and being retired 
can influence chronic pain and neuropathic pain in patients.  
As main conclusions, it was possible to verify an association between oxidative stress, and 
neuropathic pain, and, also, that weather conditions may influence the pain complaints and 
its prevalence. 
Key words 
Chronic pain, neuropathic pain, diabetes, diabetic neuropathy, oxidative stress. 
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Chronic Pain 
Usually chronic illness patients have pain and other associated symptoms that are often 
ineffectively managed and, therefore, some pain variations occur over the time (Effiong 
& Effiong, 2012). 
Pain is a useful sensation that has a protective effect in our body, working as a warning 
signal. It is characterized as an individual experience which is often hard to determine 
(Calcutt, 2013; Robison-Papp, George, Dorfman, & Simpson, 2015).  
A painful stimuli normally begins in the periphery and reaches the central nervous system 
(CNS) through pain pathways. An injury in the neuronal network may lead to an amplified 
reaction to noxious stimuli (hyperalgesia), and nociceptive response to harmless stimuli 
(allodynia) (Hagenston & Simonetti, 2014). 
Chronic pain (CP), as Diabetes, is considered a major public health problem worldwide 
with a huge impact in social and economic areas (De Moraes Vieira, Garcia, Da Silva, 
Mualem Araújo, & Jansen, 2012; Poliakov & Toth, 2011).  
Pain, particularly CP, has a great influence concerning daily activities, because induces 
alterations in mood, cognition and emotional functioning, which potentiates limitations 
in basic activities, as normal work or walking, among others (Poliakov & Toth, 2011; 
Reid et al., 2011). 
The International Association for the Study of Pain (IASP) defines CP as “persisting 
continuously or intermittently for longer than 3 months” (L. F. Azevedo, Costa-Pereira, 
Mendonça, Dias, & Castro-Lopes, 2012; Inoue et al., 2015). In terms of intensity, pain 
may be classified as mild-to-severe (L. F. Azevedo et al., 2012; Reid et al., 2011). 
CP may be nociceptive – related with tissue injury; neuropathic – when it corresponds to 
a failure in nerves or in a part of the nervous system; or both, also called mixed pain 
(Baker, Collett, Fischer, & Herrmann, 2010). 
In the past 10 years, several studies worldwide presented an estimative of people affected 
by CP (Table I). This estimative varies from 4.2 to 48% mainly due to (i) different 
definitions of CP, (ii) target population, and (iii) applied methodology for the 
investigation (De Moraes Vieira et al., 2012; Reid et al., 2011). In Europe, 19% of the 
population suffers from CP (Baker et al., 2010). 
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Table I: Prevalence of CP worldwide. 
Study Year Population % of CP 
(Torrance, Smith, Bennett, & Lee, 2006) 2006 
United 
Kingdom 
48% 
(Breivik, Collett, Ventafridda, Cohen, & Gallacher, 2006) 2006 
Europe and 
Israel 
19% 
(Bouhassira, Lantéri-Minet, Attal, Laurent, & Touboul, 2008) 2008 France 31.7% 
(Toth, Lander, & Wiebe, 2009) 2009 Canada 35.0% 
(Reid et al., 2011) 2011 Europe 19% 
(De Moraes Vieira et al., 2012) 
 
2012 Brazil 42% 
(Kurita, Sjogren, Juel, Hojsted, & Ekholm, 2012) 2012 Denmark 26.8% 
(L. F. Azevedo et al., 2012) 2012 Portugal 36.7% 
(Mohamed Zaki & Hairi, 2014) 2014 Malaysia 15.2% 
(Inoue et al., 2015) 2015 Japan 39.3% 
(Bernfort, Rahmqvist, Husberg, & Ake, 2015) 2015 Sweden 4.2-18.9% 
 
The most common sites of pain are the upper and lower back, joints, head and neck.  Also, 
spinal complications, pain after trauma and surgery are pointed as common causes of CP 
(Baker et al., 2010; Breivik, Eisenberg, & O’Brien, 2013; Reid et al., 2011). A European 
report about CP indicates NP (11%) and diabetes (4%) as common causes of CP (Figure 
I) (Baker et al., 2010)  
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Figure I: Chronic pain origins – most common causes (Baker et al., 2010). 
 
A CP condition may implicate alterations in different organs and systems, as well as 
psychiatric disorders (L. Azevedo, Pereira, Dias, & Agualusa, 2007). 
For the care of CP, it is necessary to implement a multidisciplinary intervention, 
establishing a cognitive behavioral methodology with therapeutic dialogues and training 
addressing the psychosocial aspects of CP and physical activity. Often the time until 
diagnosis is larger than expected, situated between 3 months and 5 years, which is a long 
period to manage pain without the proper treatment (Figure II). In Portugal, it takes about 
2.5 years (Baker et al., 2010; Jouini et al., 2014; Lapane, Quilliam, Benson, Chow, & 
Kim, 2014) to diagnose CP. 
 
 
Figure II: Time until diagnose (Baker et al., 2010). 
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In 2030-2050 it is expected that the range of the population over 60 years will be 1.3-2 
billion. With the population aging, the incidence and prevalence of pain is expected to 
rise. However, pain could be underestimated due to the association of elderly and pain as 
a normal process in this age group  (Bernfort et al., 2015; Kaye, Baluch, & Scott, 2010; 
Mohamed Zaki & Hairi, 2014). 
Several times, CP is associated with other comorbidities. Diabetes is one of the most 
affected conditions, and CP is a diminishing factor for patients’ quality of life (QoL) 
(Chang, Ma, Lee, & Hsieh, 2015; Liberman, Peleg, & Shvartzman, 2014; Nenke et al., 
2015)  
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Neuropathic pain 
The IASP defines neuropathic pain (NP) as “pain arising from a direct consequence of a 
lesion or disease affecting the somatosensory system”, and may result from a variety of 
different illnesses (Barbosa, Bennett, & Carvalho, 2014; Paul C Langley, Van Litsenburg, 
Cappelleri, & Carroll, 2013; Schaefer et al., 2014) 
The estimated prevalence of occurrence of NP in general population varies among 
authors: 
 3 - 17% (Mathieson, Maher, Terwee, Folly de Campos, & Lin, 2015); 
 3 - 8% (Barbosa et al., 2014); 
 7 - 8% (De Andrés, De La Calle, Pérez, & López, 2014; De Moraes Vieira et al., 
2012); 
 6.9–8.2% (Hamdan, Luna, Del Pozo, & Gálvez, 2014). 
NP is associated with nerve damage and it is characterized by spontaneous and induced 
pain, along with paresthesias, dysesthesias, and normal sensation impairment. Many 
patients describe numbness, burning, tingling in the extremities and slow nerve 
conduction as the main symptoms (Jain, Bansal, Dalvi, Upganlawar, & Somani, 2014; 
Mathieson et al., 2015; Papanas & Ziegler, 2014; Schaefer et al., 2014). It is also related 
with some comorbidities such as depression, anxiety and sleep disorders (Cortez, Reis, 
Cardoso, Onofre, & Piovezan, 2014; García-Campayo, Caballero, Perez, & López, 2012). 
The appearance of NP is associated to degenerative or age-related factors, being the 
elderly the most affected population. This condition arises in a wide and heterogeneous 
number of clinical conditions (De Andrés et al., 2014; Lekpa et al., 2013).  
Distinguish neuropathic from nociceptive pain is not often easy, therefore, questionnaires 
for NP have been developed and applied when there is suspicion of NP, because NP 
diagnosis and treatment are a challenge, and, consequently, this condition is not treated 
optimally. (Barbosa et al., 2014; Erdemoglu & Koc, 2013; Harifi et al., 2013; Mathieson 
et al., 2015; Radat, Margot-Duclot, & Attal, 2013).  
Antidepressants, anticonvulsants and opioid analgesics are among the selected drugs with 
known efficacy in the control of NP. Nevertheless, some unsatisfactory side effects are 
known and new approaches are being designed such as dihydrotestosterone (DHT) and 
3α-diol (Calabrese et al., 2014; Hamdan et al., 2014; Moulin et al., 2015; Oosterling, 
Boveldt, & Verhagen, 2015).   
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Diabetes is pointed as a major cause of NP. This condition affects up to 25 % of diabetic 
patients and has a great impact on QoL  (Barbosa et al., 2014; Freeman, 2013; Lapane et 
al., 2014; Wang et al., 2014). However, there are other causes such as infection-associated 
neuropathy (i.e. postherpetic neuralgia and HIV), cancer, stroke, lumbar or cervical 
radiculopathies, complex regional pain syndrome, spinal cord injury pain, trigeminal 
neuralgia, drug-induced polyneuropathies, multiple sclerosis, traumatic or post-surgical 
nerve injuries and central pain syndromes secondary to vascular lesions (De Andrés et 
al., 2014; Lekpa et al., 2013; Snedecor et al., 2013). 
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Diabetes 
Diabetes is an epidemic disease, considered a public health issue of great relevance, that 
has a huge impact in nowadays society, being in the top five main causes of death in 
developed countries (Bandeira et al., 2013; Chopra et al., 2012; Matough & Budin, 2012). 
Several authors estimated that about 366 million people worldwide suffer from this 
condition and that it is predictable, until 2030, an increase of 1.5 times (Chopra et al., 
2012; J. Han et al., 2014; Kandhare, Raygude, Ghosh, Ghule, & Bodhankar, 2012). 
Diabetes is associated with complications at macro and microvascular levels such as 
retinopathy, neuropathy and nephropathy (Bandeira et al., 2013; Chilelli, Burlina, & 
Lapolla, 2013; Singh, Kishore, & Kaur, 2014). Chronic hyperglycemia,  a rise of blood 
sugar, is the major contributor for this condition (Hinder, Vivekanandan-Giri, McLean, 
Pennathur, & Feldman, 2013; Jain et al., 2014; Singh et al., 2014). Alterations in cellular 
homeostasis have also a great importance, causing diffuse vascular injury and multi-organ 
dysfunction (Chilelli et al., 2013). 
Diabetes has two distinct types, type 1 diabetes (T1D) and type 2 diabetes (T2D) that are 
both characterized by impaired insulin signaling and hyperglycemia. T2D is the most 
prevalent, representing 90% to 95% of known cases (Bandeira et al., 2013; Hinder et al., 
2013; Y.-B. Wu et al., 2013). T1D patients have autoimmune lesions, which lead to 
pancreatic b-cells destruction, and loss of insulin production, while T2D patients have a 
remarkable increase in insulin production and insulin resistance in several tissues 
(muscle, fat and liver) (Hinder et al., 2013; Premkumar & Pabbidi, 2013).  
Diabetes is responsible for structural/functional damages in several organs (i.e. heart, 
blood vessels, eyes, kidneys, and nerves) (J. Han et al., 2014)  
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Diabetic Neuropathy 
Vinik and colleagues (2003) have defined diabetic neuropathy (DN) as ‘‘a demonstrable 
disorder, either clinically evident or subclinical, that occurs in setting of diabetes mellitus 
without other causes for peripheral neuropathy”. 
DN is a long-term disorder and the most common complication of diabetes worldwide 
(Al-Enazi, 2013; Kasznicki et al., 2012; Singh et al., 2014). It appears as one of the 
predominant causes of diabetes-related hospital admissions, foot ulcers and non-traumatic 
amputations in Western countries (Figueroa-Romero, Sadidi, & Feldman, 2008; Hinder 
et al., 2013). 30-40% T2D patients are affected by DN, but those with T1D have a more 
severe outcome. This condition causes incapacities, poor QoL secondary to pain and a 
high mortality rate (Al-Enazi, 2013; Figueroa-Romero et al., 2008; Kasznicki et al., 2012; 
Singh et al., 2014). 
Some disorders are closely related to DN, i.e. nerve fiber loss, demyelination and axonal 
degeneration of myelinated fibers (Al-Enazi, 2013; Chopra et al., 2012). Specific 
structural changes (nodal and paranodal swelling) in myelinated fibers are noted primary, 
and leads to disturbed axonal transport and progressive axonal atrophy (Singh et al., 
2014). Relying on the cause, the injury may appear in the axons or in the myelin sheaths 
(Hosseini & Abdollahi, 2013). 
DN is associated with some painful symptoms. Paraesthesia (spontaneous pins and 
needles sensation), hyperalgesia (increased pain responses to normally noxious stimuli) 
and allodynia (abnormal hypersensitivity to normally innocuous stimuli)  are present in 
around 20% of all diabetic patients (Areti, Yerra, Naidu, & Kumar, 2014; Gong et al., 
2015; Singh et al., 2014).  
One of the key factors in the progress of DN is the generation of free radicals by amplified 
glycolytic processes. The physiological intermediaries and metabolic initiators, resulting 
of oxidative stress (OS) and ROS, have a preponderant weight in progressive nerve fiber 
damage, dysfunction and loss in DN (Hosseini & Abdollahi, 2013). 
In diabetes the nerve tissues are in a proinflammatory state and this is a leading cause for 
the development of DN (Hosseini & Abdollahi, 2013; Kumar, Negi, & Sharma, 2012).  
Among other methods of diagnosis, the clinical  assessment, quantitative sensory testing, 
and electrophysiological study (latency, amplitudes and nerve conduction velocity of 
sensory and/or motor nerve) are the key points for determination of DN (Rajanandh, 
Kosey, & Prathiksha, 2014). 
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To monitor the progression of DN, in terms of oxidative stress measurement, and the 
response to therapeutics it is important to have some reliable biomarkers. Thus, 
malondialdehyde (MDA), reduced glutathione (GSH), superoxide dismutase (SOD) and 
activities of mitochondrial enzymes (citrate and ATP synthase) are considered valuable 
biomarkers (Areti et al., 2014). 
The most common therapeutics is the use of agents that modulate pathogenetic 
mechanisms (glycemic control), foot care and relieve the symptoms of DN (Figueroa-
Romero et al., 2008; Hinder et al., 2013; Singh et al., 2014). It is desirable that treatment 
initiates when patients notice that painful neuropathy is impairing activities of daily living 
and their QoL (Hosseini & Abdollahi, 2013; Singh et al., 2014).  
In early stages, the progress of DN should be prevented and accompanied with a suitable 
treatment (Catanzaro et al., 2013). However, DN is known as a multifactorial disease 
which undermines the choice of an effective treatment. Thus, it is very important the 
discovering of novel therapeutic agents (Cameron, 2013; Kumar et al., 2012; Papanas & 
Ziegler, 2014). 
According to Snedecor and colleagues (2013), the European Federation of Neurological 
Societies subdivided the treatment in two categories: 
 First line: tricyclic antidepressants, gabapentin, pregabalin, and serotonin-
norepinephrine reuptake inhibitors; 
 Second- or third-line: tramadol or opioids. 
The current treatment of DN includes antioxidants, antidepressants, polyphenols, 
selective serotonin reuptake inhibitors (SSRIs), antiarrhythmics, opioids, anticonvulsants 
and analgesics, but its effectiveness has limited success in clinical trials (Dieleman, 
Kerklaan, Huygen, Bouma, & Sturkenboom, 2008; Kandhare et al., 2012; Snedecor et al., 
2013). 
Pathak and colleagues (2014) has suggested that a therapeutic with atorvastatin may 
reestablish the levels of enzymatic and non-enzymatic antioxidants, helping in the relief 
of NP symptoms. 
The use of α-lipoic acid (ALA) is also suitable in the treatment DN (T. Han, Bai, Liu, & 
Hu, 2012; Papanas & Ziegler, 2014) 
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Oxidative Stress 
The overproduction of free radicals and/or reduced antioxidant protection potentially 
leads to an increase of oxidative stress (OS) (Liu et al., 2014). 
An excess of blood glucose leads to an overload of electron transport chain and, therefore, 
to the production of superoxides species. Subsequently mitochondrial and cytosolic OS 
is generated (Bandeira et al., 2013; Choi, Chandrasekaran, Inoue, Muragundla, & Russell, 
2014; Schnell et al., 2013).  
Chopra and colleagues (2012) defined OS as an “imbalance between oxidants and 
antioxidants in favor of the oxidants, potentially leading to damage”. 
Currently, OS is a main concern among biomedical research and clinical practice areas. 
OS is pointed as an important phenomenon associated with several  disease states, as 
diabetes, obesity, cancer, ageing, inflammation, neurodegenerative disorders, 
hypertension, apoptosis, cardiovascular diseases, and heart failure (Pitocco et al., 2010). 
ROS are produced in cells continuously during aerobic metabolism (Li, O, Li, Jiang, & 
Ghanbari, 2013). In mammalian cells, several enzyme systems generate ROS, comprising 
(i) nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, (ii) uncoupled nitric 
oxide (NO) synthase and (iii) the mitochondrial electron transport chain (Chopra et al., 
2012).  
The beginning of diabetes is deeply connected with OS. ROS are present and increased 
in both T1D and T2D (Singh et al., 2014). In fact, the CNS  is significantly affected by 
OS because of its needs of oxygen, diminished antioxidant capacity and neurons 
characteristics, making OS one of the main causes of neurodegenerative diseases (Li et 
al., 2013). 
In several illnesses, and specially in diabetes, the mitochondrial metabolism and the 
cascade of oxidative phosphorylation are pointed as significant contributors of ROS 
generation (Chopra et al., 2012; Figueroa-Romero et al., 2008; Li et al., 2013). This 
increased generation of ROS in cells and/or an inefficient elimination results in vascular 
dysfunction, damage in several cellular components (proteins, membrane lipids and 
nucleic acids), which potentiates the appearance of cancer, diabetes and other OS-
mediated dysfunctions (Bandeira et al., 2013; Matough & Budin, 2012). Several studies 
declared that OS was already identified as a main cause of neuronal injury in several 
neuropathies (i.e. DN, acrylamide induced neuropathy and Charcot–Marie neuropathy) 
(Areti et al., 2014; Tang et al., 2012). 
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Despite its negative impact on health, ROS have important cellular activities, namely, as 
mediators of intracellular signaling cascades and as defense mechanism (i.e. 
phagocytosis, neutrophil function, macrophages and other cells of immune system) (Li et 
al., 2013; Matough & Budin, 2012). 
The protective cellular machinery, through antioxidant enzymes and non-enzymatic 
antioxidants, allows the regularization of ROS levels in all cells (Li et al., 2013; Matough 
& Budin, 2012).  Nevertheless, an imbalance between the production of ROS and the 
decrease of endogenous antioxidant power spread the effects of OS, causing endothelial 
dysfunction, insulin resistance and alterations in pancreatic β-cells (Bandeira et al., 2013). 
Li and colleagues (2013) reported that the free radicals of ROS might easily pass through 
the plasma membrane, leading to cell membrane injuries via lipid peroxidation, 
modification of the signal and alterations of the structural proteins conducting to 
misfolding and aggregation, and oxidation of RNA/DNA interrupting transcription and 
resulting in gene mutation. 
In diabetic state, the increased production of ROS is related with hyperglycemia, and is 
indicated as a major complication of diabetes (Matough & Budin, 2012). 
In OS conditions, mitochondria has a major role, once it normalizes this metabolic 
dysregulation state. An increase in ROS (Table II) results in ions in the intramitochondrial 
space, which leads to damage in cellular functions (Bandeira et al., 2013). 
 
Table II: Overview of different types of reactive oxygen species (adapted from (Bandeira et al., 2013)). 
ROS Reactivity Source Activity 
Superoxide 
anion radical  
(●O2-) 
Low 
Phagocytic cells, autoxidation 
reactions, enzymatic reactions, 
smoking 
Vascular regulation, response to OS and 
maintenance of redox homeostasis 
Hydrogen 
peroxide (H2O2) 
Low 
Mitochondrial matrix,  ●O2-  
dismutation by SOD, xanthine 
dehydrogenase, smoking 
May generate ●OH radical in the 
presence of transition metals, inactivate 
enzymes through oxidation of essential –
SH groups. 
Hydroxyl 
radical  
(●OH) 
High 
Water radiolysis, reaction of  ●O2-  
with H2O2 and in the presence of 
transition metals, water ozonation 
May damage DNA, proteins, lipids and 
carbohydrates 
Singlet oxygen 
(O21) 
High 
Phagocytes, light induction, 
radiation, reactions catalyzed by 
peroxidases, smoking and others 
Direct DNA and protein damage, initiates 
lipids peroxidation and produces alcoxyl 
and peroxyl radicals 
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The pathways dysregulation indicated above, and caused by DN, are the major source of 
cellular damage, producing an imbalance in body’s redox homeostasis, resulting in OS 
(Areti et al., 2014; Negi, Kumar, Joshi, & Sharma, 2011; Singh et al., 2014), which 
damage the exposed neurons, conducts to apoptosis and prevents neurite outgrowth, 
consequently resulting in an impair of normal neuronal process (Chopra et al., 2012).  
OS may increase neurodegeneration through different paths, such as (i) bioenergetic 
failure, (ii) depletion of antioxidant defenses, (iii) biomolecular damage, (iv) 
microtubular disruption, (v) ion channel activation, (vi) demyelination, (vii) 
neuroinflammation, (viii) mitophagy impairment and (ix) neuronal death through 
apoptosis (Areti et al., 2014).  
Along with OS, several crucial factors in regulation of homeostasis (metabolic and 
vascular pathways) are altered in DN (Figure III), such as: 
 advanced glycation end product formation (AGEs) (Al-Enazi, 2013; Bandeira et 
al., 2013; Chilelli et al., 2013; Chopra et al., 2012; T. Han et al., 2012; Hosseini 
& Abdollahi, 2013; Jain et al., 2014; Kandhare et al., 2012; Liu et al., 2014; Negi, 
Kumar, & Sharma, 2011; T. Zhang, Gong, & Zhou, 2013); 
 increased protein kinase C (PKC) activity (Bandeira et al., 2013; Chopra et al., 
2012; T. Han et al., 2012; Hosseini & Abdollahi, 2013; Jain et al., 2014; Kandhare 
et al., 2012; Liu et al., 2014; Negi, Kumar, Joshi, et al., 2011; Singh et al., 2014; 
T. Zhang et al., 2013); 
 activation of poly ADP-ribose polymerase (PARP) (Al-Enazi, 2013; T. Han et al., 
2012; Hosseini & Abdollahi, 2013; Jain et al., 2014; Kandhare et al., 2012; Negi, 
Kumar, Joshi, et al., 2011); 
 hexosamine pathway (Bandeira et al., 2013; Chopra et al., 2012; T. Han et al., 
2012; Hosseini & Abdollahi, 2013; Jain et al., 2014; Kandhare et al., 2012; T. 
Zhang et al., 2013); 
 polyol pathway (Al-Enazi, 2013; Bandeira et al., 2013; Chopra et al., 2012; 
Hosseini & Abdollahi, 2013; Kandhare et al., 2012; Liu et al., 2014; Singh et al., 
2014; T. Zhang et al., 2013); 
 inflammation (Hosseini & Abdollahi, 2013; Kumar et al., 2012; Negi, Kumar, 
Joshi, et al., 2011). 
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Figure III: In diabetes, several OS pathways are impaired due to hyperglycemia. 
AngII: angiotensin II; eNOS: endothelial nitric oxide synthase; Jac/STAT: janus kinase (Jac)-signal 
transducer and activator of transcription (STAT); LDL: low density lipoprotein cholesterol; MAPK: 
mitogen-activated protein kinase; MetS: metabolic syndrome; NF-κb: nuclear transcription factor κb; •NO: 
nitric oxide; NOS: nitric oxide synthase; •O2−: superoxide anion radical; •OH: hydroxyl radical; ONOO−: 
peroxynitrite; PCKδ: protein kinase C δ. (Bandeira et al., 2013). 
 
AGEs and polyol pathways cause the modification of redox ability by disturbing 
glutathione recycling or through increasing ROS production. Other pathways like 
hexosamine, PKC and PARP have an important role in injury due to increased expression 
of inflammatory proteins (Brownlee, 2005; Hosseini & Abdollahi, 2013). 
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Objectives 
1. To investigate the eventual relation between chronic pain, diabetes and oxidative 
stress. 
2. To describe the average biomarkers effect and summarize its statistical 
significance. 
3. To predict likely clinical benefit for future groups of patients. 
4. To determine the socio-demographic characteristics of the convenience sample in 
each season (summer, autumn, winter and spring). 
5. To determine the duration and etiology of pain, the associated pathologies and 
usual medication in each season (summer, autumn, winter and spring). 
6. To characterize the pain: local, intensity, impact, relief by medication and its 
effect on daily activities, using Brain Pain Inventory (BPI) questionnaire.  
7. To determine the main features associated with neuropathic pain, using Douleur 
Neuropathique 4 (DN4) questionnaire. 
 
In figure IV are represented the three key points of this thesis. We intend to study an 
eventual relation between this three major and current subjects: chronic pain, diabetes and 
oxidative stress 
 
 
 
Figure IV: Key points of thesis. 
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Chapter II – Oxidative Stress in Diabetic 
Neuropathy – a meta-analysis 
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Abstract 
Several studies reported a connection between oxidative stress (OS) dysregulation and 
diabetic neuropathy (DN). This meta-analysis intend to analyze the clinical data 
quantitatively by comparing the OS biomarkers between diabetic neuropathic models and 
healthy controls. 
A PubMed search was conducted to collect the studies that related OS and DN from 1995 
to 2015. The effect sizes for the standardized mean differences were expressed through 
Hedges's G and a Z-score; a p-value of <0.05 for Z was considered statistically significant. 
The search originated 275 studies, and 9 studies met the inclusion criteria. The 
biochemical parameters assessed were: superoxide dismutase (SOD, n=6); lipid 
peroxidation (LPO, n=4); reduced glutathione (GSH, n=2) and catalase (CAT, n=2). 
Compared to health control, DN models showed significantly higher LPO (ρ < 0.05), and 
significantly lower CAT, SOD and GSH (ρ < 0.05). It was verified high heterogeneity 
between the studies (I2 > 60%), except for CAT analysis (I2 = 0%). 
Thus, data indicated that the evaluated OS biomarkers may have clinical significance and 
may be useful in DN diagnostic, representing a possible relation between OS and DN. 
Introduction 
Currently, diabetes corresponds to an epidemic disease characterized by chronic 
hyperglycemia. This may conduct to the development of DN with macro and 
microvascular damages (Bandeira et al., 2013; Jain et al., 2014; Premkumar & Pabbidi, 
2013). 
Neuropathy is an emergent condition and yet it’s still not established any theory as the 
main cause for this condition. Nevertheless neurons are very sensitive to reactive oxygen 
species (ROS) and its elevation intracellularly may lead to cell injury (Hassler, Johnson, 
& Hulsebosch, 2014; Nikolic et al., 2014; Visnagri et al., 2014). Neuropathy has an 
elevated prevalence which is enhanced with the duration of the disease (Premkumar & 
Pabbidi, 2013).  
DN arises as a chronic common and significant complication of diabetes. 50–60 % of 
diabetic patients may have associated neuropathies (Kumar et al., 2012). Hence, its 
evolution has great effect in the diabetes prognosis and it’s a burden for health economy 
(Jain et al., 2014; Kumar et al., 2012; Liu et al., 2014). Age and duration of diabetes are 
key factors in the development of neuropathy (Tang et al., 2012)  
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DN is a condition described by a sensitivity loss (i.e. chemical, thermal, and mechanical 
sensations) (Mathieson et al., 2015; Premkumar & Pabbidi, 2013). Spontaneous pain, 
allodynia and hyperalgesia are among the complaints of  DN patients (Kandhare et al., 
2012; Stavniichuk, Shevalye, Hirooka, Nadler, & Obrosova, 2012; Zhao et al., 2014). 
Several studies pointed hyperglycemia as the main source of OS, which may be a leading 
cause in the development of sciatic nerve dysfunction in diabetic models (Y. B. Wu et al., 
2012). OS is pointed in several studies as having an important role on the pathogenic 
mechanism of DN. OS may arise from a hyperglycemic state, and is described as one of 
the responsible mechanisms for the neuronal injury and loss of function in diabetes (Areti 
et al., 2014; T. Han et al., 2012; Premkumar & Pabbidi, 2013).  
Diabetes has a strong association with increased OS levels, as a result of either amplified 
production of free radicals or reduced antioxidant defenses (T. Han et al., 2012; Pitocco 
et al., 2010). 
The maintenance of ROS levels in all cells is accomplished by the production of 
antioxidant enzymes and non-enzymatic antioxidants, leading to the regulation of 
homeostasis (Li et al., 2013; Matough & Budin, 2012). Some antioxidant enzymes are 
described as part of the OS regulation, such as SOD and CAT, with protection functions 
(Bandeira et al., 2013; Kasznicki et al., 2012). 
To monitor the progression of DN and its response to therapeutics it is important to 
evaluate some reliable biomarkers. Several OS biomarkers could be assessed to evaluate 
the cellular oxidative status, such as CAT, GSH, LPO and SOD, among others (Areti et 
al., 2014). 
CAT is a key enzyme which converts hydrogen peroxide into water and oxygen, 
transforming a ROS in a non-toxic molecule (Bandeira et al., 2013; Kasznicki et al., 2012; 
Nikolic, Stanimirovic, Bjelogrlic, & Isenovic, 2014).  
GSH is a key enzyme in cellular protection against sulfahydryl group of cysteine in 
proteins, being an extremely efficient scavenger for ROS. It stands out as non-enzymatic 
antioxidant, being present in all tissues. When its concentration is higher in the cell it 
becomes more resistant to OS, and, consequently, GSH becomes an excellent OS 
biomarker  (Guedes et al., 2009; Kulkarni, Acharya, Ghaskadbi, & Goel, 2014; Pathak et 
al., 2014; Visnagri, Kandhare, Chakravarty, Ghosh, & Bodhankar, 2014). Moreover, 
hydroxyl radicals are only scavenged by GSH (Pathak et al., 2014).  
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SOD is a protecting enzyme for aerobic organisms from the  toxicity of superoxide 
radical, and also responsible for redox balance in neuron (Hybertson, Gao, Bose, & 
McCord, 2011; Visnagri et al., 2014). Superoxide radicals are transformed into oxygen 
and hydrogen peroxide by SOD, through a dismutation reaction (Bandeira et al., 2013; 
Kasznicki et al., 2012; Pathak et al., 2014). 
Free radicals attack several biomolecules (amino acids, lipids, proteins and DNA),  being 
the lipids the most vulnerable (Bandeira et al., 2013; Ilechukwu, Ebenebe, & Ubajaka, 
2014; Tiwari, Pandey, Abidi, & Rizvi, 2013). Malondialdehyde (MDA) acts in cell 
membranes promoting nerve damage. Thus, LPO, measured in terms of MDA production, 
is a reliable biomarker being frequently used in the assessment of cellular OS status 
(Bandeira et al., 2013; Tiwari et al., 2013; Visnagri et al., 2014). Lipoperoxides and 
reactive aldehydes, as MDA, are produced by breakdown of polyunsaturated fatty acids 
present in cell membrane by ROS (Bandeira et al., 2013; Catanzaro et al., 2013; Jakuš & 
Sándorová, 2014).  
To our knowledge, a meta-analysis of studies about oxidative stress biomarkers in DN is 
missing. This study intends to analyze the clinical data quantitatively by comparing 
oxidative stress biomarkers between healthy and diabetic neuropathic models, through a 
systematic review and meta-analysis of OS biomarkers, as predictive of poor prognostic 
for diabetic neuropathy. 
Materials and Methods 
We performed a systematic review and meta-analysis of published works about oxidative 
stress markers, as risks factors for diabetic neuropathy, according to Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Hutton et al., 
2015). 
i. Search procedures  
The study was conducted according to PRISMA directives. In order to identify the 
studies, an electronic search in September 2015, with no linguistic restriction, was 
conducted, researching one database – Medline (PubMed). The Boolean search was 
conducted according to the following keywords: Diabetic Neuropathies [AND] Oxidative 
Stress. Two investigators evaluated, independently, the titles and abstracts of the papers 
identified as of potential relevance in the inclusion criteria. Where a title or abstract could 
not be included for certainty, a third corrector helped decide whether to reject it or not.  
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ii. Inclusion criteria  
The papers which satisfied the following inclusion criteria were selected: (i) presence of 
following keywords in the abstract: diabetic neuropathy and oxidative stress or reactive 
oxygen species; (ii) performed in human or in mouse models; (iii) studies that presented 
clinical data for OS biomarkers, such as CAT, GSH, LPO, SOD and 8-hydroxy-2'-
deoxyguanosine (8-OHdG); (iv) studies that provided subject numbers, means and 
standard deviations for controls and diabetic neuropathic models; (v) studies performed 
in sciatic nerve samples; and (vi) studies presented the same or convertible units for each 
OS biomarker. 
iii. Exclusion criteria 
Studies were excluded from our analysis if they met the following criteria: (i) reviews; 
(ii) aren’t written in English; and (iii) studies with subjects’ numbers defined as an 
interval (i.e. n=5-7). 
iv. Statistics 
A separated meta-analysis was performed for each OS biomarker, which >2 studies 
provided data, comparing levels in diabetic neuropathic models with those in healthy 
controls. A fixed-effects model was used and standardized mean differences weighted for 
sample size were calculated, using RevMan version 3.3.070. The effect sizes for the 
standardized mean differences were expressed through Hedges's G and a Z-score; a p-
value of <0.05 for Z was considered statistically significant. The between-study 
heterogeneity was determined using the Cochrane's Q statistic and expressed using I2. 
 
Results 
Figure V shows the results of the literature search, screening and review for studies 
eligible for inclusion in the meta-analysis. The search generated 257 papers between 1994 
and 2015: of these, 29 were excluded because were reviews and 31 because weren’t 
written in English; 197 publications were reviewed for eligibility: 120 articles presented 
the terms DN and OS or ROS in the abstract, 74 articles were included for the meta-
analysis, 13 studies were excluded because presented subjects number defined as an 
interval, and 52 full-text articles were excluded based on the inclusion/exclusion criteria.  
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Figure V: Literature search results 
MeSH – medical subject headings; DN – diabetic neuropathy; OS – oxidative stress; ROS – reactive oxygen species  
257 studies were 
generated by MeSH 
terms search on 
PubMed
197 studies were 
reviewed for 
eligibility
120 studies 
presented the terms 
DN and OS or ROS 
in the abstract
74 studies presented 
data in human or 
mouse models
61 studies have 
subjects number 
defined as a single 
number
9 studies met the 
inclusion criteria
n=9
52 studies didn't met 
the inclusion criteria
13 studies have 
subjects number 
defined as an interval
46 studies presented 
data in another 
biological models
77 studies didn't 
presented DN and 
OS or ROS in the 
abstract
31 studies were 
reviews
29 studies weren't 
written in English
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Our research identified 9 studies which measured antioxidant enzymatic activities (SOD 
and CAT), antioxidant non-enzymatic activity (GSH) and LPO in sciatic nerve of mouse 
model, streptozotocin-induced (STZ), according to the inclusion criteria. These studies 
included a total of 66 diabetic neuropathic models and 71 healthy controls. 
Table III presents the included studies and their OS biochemical indicators. Five of the 
included studies analyzed just one OS biomarker and the others analyzed two or more.  
The biochemical parameters assessed were: (i) SOD – 6 studies; (ii) LPO – 4 studies; (iii) 
GSH – 2 studies, and (iv) CAT – 2 studies.
  
 
 
2
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Table III: Included studies in the meta-analysis for diabetic neuropathy and oxidative stress in mouse model, and their biochemical indicators for oxidative stress. 
Study 
Biological 
model 
N 
LPO (nmol MDA/mg 
protein) 
SOD (units/mg) 
CAT (μmoles of H2O2 
decomposed/min/mg) 
GSH (nmol/mg protein) 
Control DN Control DN Control DN Control DN Control DN 
(Visnagri et al., 2014) 
Sprague-
Dawley rat 6 6 ND ND 24,12±1,53 6,14±0,52 ND ND ND ND 
(Rao et al., 2014) 
Wistar rat 6 6 ND ND 32,00±2,00 10,00±0,00 ND ND ND ND 
(Y. B. Wu et al., 
2012) 
Sprague-
Dawley rat 15 13 1,97±0,18 4,55±0,52 82,95±7,17 59,93±7,23 ND ND ND ND 
(Kandhare et al., 
2012) 
Wistar rat 
6 6 ND ND 29,46±0,83 5,78±0,89 ND ND ND ND 
(Baluchnejadmojarad, 
Roghani, & 
Khastehkhodaie, 
2010) 
Wistar rat 
8 8 4,00±1,00 10,50±1,5 ND ND ND ND ND ND 
(Kamboj, Vasishta, & 
Sandhir, 2010) 
Wistar rat 
6 6 1,63±0,14 2,31±0,22 2,17±0,30 1,11±0,12 1,05±0,08 0,5±0,17 5,15±0,24 3,21±0,24 
(Kuhad & Chopra, 
2009) 
Wistar rat 
7 7 1,94±0,04 3,58±0,11 12,44±0,09 4,32±0,51 ND ND ND ND 
(Stevens, Obrosova, 
Cao, Van Huysen, & 
Greene, 2000) 
Wistar rat 
9 8 ND ND ND ND 0,11±0,01 0,08±0,01 ND ND 
(Nagamatsu et al., 
1995) 
Mouse 
(without 
model 
definition) 
8 6 ND ND ND ND ND ND 8,00±0,80 5,00±0,60 
ND – not defined; DN – diabetic neuropathic LPO – lipid peroxidation; SOD – superoxide dismutase; CAT – catalase; GSH – reduced glutathione; MDA – malondialdehyde.  
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Figures VI to IX represented the forest plots for LPO, CAT, SOD and GSH, respectively. 
Results displayed a significant increase in LPO levels in DN (Figure VI), ρ-value < 0.05, 
with a large effect size. 
Concerning CAT activity, the results showed a significant decrease in this biomarker in 
DN (Figure VII), ρ-value < 0.05, with a large effect size. 
Results for SOD activity presented a significant decrease in this biomarker in DN (Figure 
VIII), ρ-value < 0.05, with a large effect size. 
Regarding GSH, the results showed a significant decrease in this biomarker in DN (Figure 
IX), ρ-value < 0.05, with a large effect size. 
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Figure VI: Lipid peroxidation in diabetic neuropathy by study. 
Effect size (Hedges’s g) estimates and 95% confidence intervals (CIs) for LPO parameter. 
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Kuhad 2009 18,55 4,17 17,39 10,38 26,72 4,45 0,00
Kamboj 2010 3,40 1,03 1,05 1,39 5,41 3,32 0,00
Baluchnejadmojarad 2010 4,82 1,10 1,21 2,66 6,98 4,38 0,00
Wu 2012 6,64 1,03 1,06 4,62 8,66 6,45 0,00
5,24 0,60 0,36 4,06 6,42 8,73 0,00
-27,00 -13,50 0,00 13,50 27,00
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Lipid peroxidation
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Figure VII: Catalase activity in diabetic neuropathy by study. 
Effect size (Hedges’s g) estimates and 95% confidence intervals (CIs) for CAT activity. 
 
 
 
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Stevens 2000 -2,85 0,67 0,45 -4,16 -1,53 -4,24 0,00
Baluchnejadmojarad 2010 -3,91 0,84 0,70 -5,56 -2,27 -4,67 0,00
-3,26 0,52 0,27 -4,29 -2,24 -6,23 0,00
-6,00 -3,00 0,00 3,00 6,00
Favours A Favours B
Catalase
Meta Analysis
Eva
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Figure VIII: Superoxide dismutase activity in diabetic neuropathy by study. 
Effect size (Hedges’s g) estimates and 95% confidence intervals (CIs) for SOD activity. 
 
 
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Kuhad 2009 -20,76 4,66 21,70 -29,89 -11,63 -4,46 0,00
Kamboj 2009 -4,28 1,21 1,47 -6,66 -1,91 -3,53 0,00
Kandhare 2012 -25,40 6,35 40,36 -37,85 -12,95 -4,00 0,00
Wu 2012 -3,11 0,59 0,34 -4,25 -1,96 -5,29 0,00
Rao 2014 -14,36 3,62 13,12 -21,46 -7,26 -3,96 0,00
Visnagri  2014 -14,52 3,66 13,42 -21,71 -7,34 -3,96 0,00
-4,12 0,51 0,26 -5,13 -3,12 -8,05 0,00
-39,00 -19,50 0,00 19,50 39,00
Favours A Favors B
Superoxide dismutase
Meta Analysis
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Figure IX: Reduced glutathione in diabetic neuropathy by study. 
Effect size (Hedges’s g) estimates and 95% confidence intervals (CIs) for GSH parameter. 
 
 
 
 
 
Study name Statistics for each study Hedges's g and 95% CI
Hedges's Standard Lower Upper 
g error Variance limit limit Z-Value p-Value
Nagamatsu 1995 -3,88 1,02 1,04 -5,88 -1,88 -3,81 0,00
Kamboj 2010 -7,46 1,95 3,79 -11,28 -3,65 -3,83 0,00
-4,65 0,90 0,82 -6,42 -2,88 -5,15 0,00
-12,00 -6,00 0,00 6,00 12,00
Favours A Favors B
Reduced glutathione
Meta Analysis
Eva
lua
tion
 co
py
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Overall, the heterogeneity of studies was high, except for CAT activity (I2 = 0%), (Table 
IV), which led us to investigate whether the sources of sampling or the assays were the 
potential contributors for such heterogeneity. 
 
Table IV: Heterogeneity of standardized mean group differences for oxidative stress markers in diabetic 
neuropathic models compared with healthy controls. 
Biomarker Heterogeneity 
I2 (%) 
LPO 81 
SOD 88 
CAT 0 
GSH 62 
 
LPO was increased in all the studies; while SOD, GSH and CAT biomarkers were 
diminished in all the studies; when comparing the diabetic group with the healthy 
controls. Table V shows the sensitivity and specificity of each biomarker and it was 
possible verify that all the biomarkers are specific and sensitive. 
 
Table V: Values of sensitivity and specificity of each analyzed biomarker. 
Biomarker Sensitivity Specificity 
LPO 34/34 = 1 36/36 = 1 
SOD 44/44 = 1 46/46 = 1 
CAT 16/16 = 1 17/17 = 1 
GSH 12/12 = 1 14/14 = 1 
 
Discussion 
The main outcome of this meta-analysis is the presence of amplified OS in DN; our results 
exhibited increased LPO and decreased CAT, GSH and SOD concentrations in DN 
models compared to healthy controls.  
Based on our meta-analysis results, four biomarkers more often used (LPO, GSH, SOD 
and CAT) were selected. 
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In accordance with our results, most of studies that analyzed CAT found that its 
concentration was decreased in diabetic models both experimental (Kumar, Kaundal, 
Iyer, & Sharma, 2007; Ranjithkumar, Prathab Balaji, Balaji, Ramesh, & Ramanathan, 
2013; Saini, Kumar, & Sharma, 2007; Sayyed, Kumar, & Sharma, 2006; Sharma & 
Sayyed, 2006; Valsecchi et al., 2011) and clinical (Arya, Pokharia, & Tripathi, 2011; 
Kasznicki et al., 2012), but Kelloog and Pop-Busui (2005) reported an elevation in this 
enzyme in their study about peripheral nerve dysfunction in diabetes. 
Several studies, in mouse models, reported a decrease in the activity of antioxidant 
enzyme – SOD (Catanzaro et al., 2013; Jain et al., 2014; Jin, Lee, Wu, Baek, & Park, 
2014; Kelloog & Pop-Busui, 2005; Mirshekar, Roghani, Khalili, Baluchnejadmojarad, & 
Moazzen, 2010; Saini et al., 2007; Sayyed et al., 2006; Sharma & Sayyed, 2006; Zhao et 
al., 2014), in agreement with our data. Also, in peripheral blood of T2D patients with 
distal symmetric polyneuropathy a reduction in SOD concentration was found (Kasznicki 
et al., 2012). Nevertheless, other studies indicated a raise in SOD activity both in diabetic 
patients (lymphocytes lysate) (Arya et al., 2011) and diabetic mouse models (Ilnytska et 
al., 2006; Valsecchi et al., 2011).  
In our study, the GSH levels were diminished in diabetic rat models, which is in 
accordance with several studies (Al-Enazi, 2013; Comelli et al., 2010; Low, Nickander, 
& Tritschler, 1997; I G Obrosova, Fathallah, Lang, & Greene, 1999; Irina G Obrosova, 
Fathallah, & Stevens, 2001; Song et al., 2003; Yu et al., 2014). The GSH levels are, also, 
decreased in diabetic patients (El Boghdady & Badr, 2012). Camera and Picardo (2002) 
identified some limitations related to the family of GSH biomarkers: the available results 
in the literature fluctuate over 10-fold, which may happen in consequence of GSH 
autoxidation and the fast proteolysis of GSH and GSSG in biological samples. Guedes et 
al. (2009) worked with the sciatic nerve of Wistar rats and verified that GSH variations 
were independent of neuropathic pain. Nevertheless, an increase in GSH/GSSG ratio was 
confirmed only in a sciatic nerve rat model, which indicate a positive association with 
NP.  
ROS are generated in an OS environment, which leads to cellular LPO (Rao et al., 2014). 
Thus, lipids are molecules with several unsaturated bonds and consequently larger. Due 
to these characteristics they are suitable to oxidative damage, causing end products of 
lipoperoxidation, which are toxic, leading to tissue damaging by free radicals (Brown, 
Andreazza, & Young, 2014; Rao et al., 2014). Several of the reviewed studies reported a 
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higher level of LPO markers in diabetic rodents, which is in accordance with our data 
(Hosseini et al., 2010; Pabreja, Dua, Sharma, Padi, & Kulkarni, 2011; Y. P. Zhang et al., 
2013), as well as in diabetic patients (Arya et al., 2011; El Boghdady & Badr, 2012; 
Hoeldtke, Bryner, & Vandyke, 2011; Sayın et al., 2014). 
The sciatic nerve becomes more affected by OS in presence of low levels of SOD and 
GSH, and high levels of LPO. This evidence increases with the duration of diabetes 
(Kamboj et al., 2010; Visnagri et al., 2014). 
In agreement with the abovementioned for each OS biomarker, the pooled effect sizes 
showed that alterations in antioxidant enzymes (SOD and CAT), LPO and GSH were 
significant, when comparing the diabetic neuropathic group with the healthy controls. 
All the OS biomarkers presented high values for heterogeneity, except CAT that showed 
no heterogeneity. Nevertheless: (i) in the forest plot for LPO,  the error bars for each study 
include the summary result (except one), which may suggest that statistical heterogeneity 
is not a problem ; (ii) for SOD, only 1/3 of the studies presented the error bars for each 
study include the summary result, which suggests that statistical heterogeneity could be 
a problem in the evaluation of this OS biomarker; (iii) in the forest plots for CAT and 
GSH,  the error bars for each study include the summary result, which may suggest that 
statistical heterogeneity is not a problem, accordingly to Fletcher (2007). The  I2 = 0% for 
CAT may indicate that all variability in effect size estimates is in consequence to 
sampling error within studies. On the other hand, values above 50% for I2 may indicate 
true heterogeneity between studies (Huedo-Medina, Sánchez-Meca, Marín-Martínez, & 
Botella, 2006). 
Rücker and colleagues (2008) pointed some major causes for heterogeneity: (i) clinical 
baseline heterogeneity ; (ii) statistical heterogeneity, and (iii) heterogeneity from other 
causes. 
The assessment of diagnostic tests quality is a point of interest of clinical and 
epidemiological research. Thus, concerning the obtained sensitivity and specificity values 
for each OS biomarker – 1 for each, which is the possible maximum value. So, with the 
appropriate validation, there is a possibility that the OS biomarkers could be used as a 
diagnostic biomarkers for DN along the clinic evaluation, as well as prevention strategies 
and to monitor the response for the treatment. We proposed the use of LPO, SOD, GSH 
and CAT as OS biomarkers in prognostic/diagnostic of DN. 
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The STZ diabetes is considered a trustworthy, reproducible and well described animal 
model (rodent) for assessment of diabetes and DN. The STZ rats show biochemical, 
oxidative and metabolic changes that mimic the humans. (Catanzaro et al., 2013; 
Kandhare et al., 2012; Rao et al., 2014; Visnagri et al., 2014). 
The main limitations in this meta-analysis are (i) the expression of the results is a 
recognized constraint manly due to the use of diverse parameters (i.e. fluid or lysate 
volume, tissue weight, cell number) which difficult the comparison between methods 
(Camera & Picardo, 2002); (ii) the study of GSH and other OS stress biomarkers in 
biological samples is problematic because of the lack of standard values (Monostori, 
Wittmann, Karg, & Túri, 2009); (iii) the low number of included studies (Brown et al., 
2014; Flatow, Buckley, & Miller, 2013; Solmi et al., 2015); (iv) between-study 
heterogeneity (Brown et al., 2014; Flatow et al., 2013; Solmi et al., 2015); and  (v) the 
laboratory methodology (Brown et al., 2014; Flatow et al., 2013). 
In conclusion, the achieved results are in agreement with the majority of the reviewed 
literature, which reported an increase in OS as an important factor in DN development. 
The reduction of SOD is considered an evidence of amplified damage by ROS and 
reduced oxidative defense  in experimental DN, therefore it was expected a decreased in 
SOD, CAT and GSH activities due to the impairment of antioxidant defenses caused by 
the elevation of ROS. SOD concentration decrease results in increased production of 
superoxide radicals. The transformation of hydrogen peroxide from water and oxygen 
which results into hydroxyl radical production is impaired in consequence of CAT 
activity reduction. Thereby, an increase of hydroxyl radicals is a leading cause for 
increased LPO.   
Thus, knowing the cause and effects in daily life of DN patients will improve their 
treatments and care. These biomarkers should be detected to support a crucial diagnosis 
and treatment of DN. 
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Chapter III – Main Characteristics of Pain 
Assessed in Patients Using BPI and DN4 
Surveys 
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Abstract 
Data collections on chronic pain (CP) are scarce in Portugal. This study aims to 
investigate the prevalence of neuropathic pain (NP) and possible associated factors in 
patients of a medical clinic in Porto. 
The data were collected during four seasons (summer, autumn, winter and spring), 
between July 2014 and June 2015 in a Porto medical clinic. In addition to 
sociodemographic and clinical data collection, two internationally validated 
questionnaires, Brief Pain Inventory (BPI) and Douleur Neuropathique 4 (DN4), were 
applied.  
A total of 84 patients reported pain symptoms. The patients mean age was 63±15.5 years 
old, 82% were women, had pain for more than 3 months, indicated often more than one 
associated comorbidity and use of medication regularly. The most frequent pain locations 
were the lumbar, hip, thigh and leg locations, with the highest peaks on autumn. Shoulder, 
arm and forearm were transversal to 4 seasons. The autumn is the season in which the 
patients declared to have more pain, referring to the minimal pain in previous week with 
a score of 4±2 (0-10 pain scale). Nearly 50% of evaluated participants had NP as 
determined by a DN4 score > 4. Spring was the season more associated with NP 
complaints. 
Our results support the need of an accurate diagnose for CP with neuropathic 
characteristics, hence the treatment is different from the one used for nociceptive pain. 
Uncontrolled pain is associated with a huge impact on patients daily routine. Also, results 
obtained support the belief that weather may influence pain complaints. 
 
Keywords: Chronic pain, neuropathic pain, diabetes, diabetic neuropathy 
Introduction 
Pain is as a warning signal to the body, acting as a protective response from an injury 
(Calcutt, 2013; Robison-Papp et al., 2015). 
CP, due to its persistent daily interferences, is a condition with a huge impact in QoL 
(Erdemoglu & Koc, 2013; Poliakov & Toth, 2011). 
CP is defined by the International Association for the Study of Pain (IASP) as “persisting 
continuously or intermittently for longer than 3 months” (L. F. Azevedo et al., 2012; 
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Inoue et al., 2015) . Concerning intensity, pain may be classified as mild-to-severe (L. F. 
Azevedo et al., 2012; Reid et al., 2011). 
According to De Moraes Vieira and colleagues (2012) the different values found for CP 
prevalence may vary mainly in consequence to (i) different definitions of CP, (ii) target 
population, and (iii) applied methodology for the investigation. Some recent studies 
indicate that prevalence of CP range from 4.2 to 42 % (L. F. Azevedo et al., 2012; Bernfort 
et al., 2015; De Moraes Vieira et al., 2012; Inoue et al., 2015; Kurita et al., 2012; 
Mohamed Zaki & Hairi, 2014; Reid et al., 2011) of the population. 
CP is often related with other comorbidities, such as diabetes, hypercholesterolemia and 
hypertension, decreasing the patient’s quality of life (QoL) (Chang et al., 2015; Liberman 
et al., 2014; Nenke et al., 2015). 
NP is defined by IASP as “pain arising from a direct consequence of a lesion or disease 
affecting the somatosensory system”, and may result from a variety of different diseases. 
Its prevalence varies among the authors between 3 and 17 % (Barbosa et al., 2014; De 
Andrés et al., 2014; De Moraes Vieira et al., 2012; Hamdan et al., 2014; Mathieson et al., 
2015). 
This study will permit the achievement of more insight in the prevalence, severity, and 
treatment of neuropathic symptoms in patients with moderate to severe pain and its 
interference with daily activities. The study was conducted in a Portuguese medical clinic: 
Clínica Médica Povo Portuense (CMPP), Porto – Portugal. 
Methods 
i. Study design 
The population was a convenience sample, which included patients of CMPP that 
voluntarily and by personal contact agreed to participate in the study. The sample was a 
group of selected patients from medical consultation at CMPP, between July 2014 and 
June 2015 at specific periods: (i) summer (July – September); (ii) autumn (October – 
December); (iii) winter (January – March); and (iv) spring (April – June). The patients 
were excluded from the study if they were unable to understand the study objectives or 
complete the questionnaires. This was an observational, cross-sectional epidemiologic 
study. This study was approved by Escola Superior de Tecnologia da Saúde do Porto 
Ethics Commission and each patient signed an informed consent. 
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ii. Data Collection Instruments 
Two surveys were applied during the consultations: (i) a Portuguese version of BPI (Short 
Form), with translation, cultural adaptation and validation by Faculdade de Medicina da 
Universidade do Porto, with the permission of the author, Charles Cleeland, PhD. BPI 
permits the assessment of important pain characteristics (i.e. intensity and location, and 
the efficacy of pain therapy) and also allows the evaluation of the pain interference in 
patient's daily routine (Erdemoglu & Koc, 2013). This questionnaire is validated and 
widely used to evaluate the severity of pain and the effect of pain on daily occupations. 
It is specified if the pain varies in intensity during the day and defined the highest, lowest, 
and average intensity of pain in the previous week, on a 0-10 scale (0 = no pain, 10 = 
worst pain imaginable); (ii) a Portuguese version of Neuropathic Pain Questionnaire from 
French Neuropathic Pain Group, with translation, cultural adaptation and validation by 
Faculdade de Medicina da Universidade do Porto, with the permission of the author, 
Didier Bouhassira, PhD. DN4 is a validated screening tool for NP. It consists of a scale 
with 10 items and is divided into four sections. A score of one is given for each positive 
item and zero for each negative item, and the total is calculated as the sum of the 10 items. 
A total score of four or more indicates NP.  
Prior the application of the surveys above mentioned a socio-demographic 
characterization that includes gender, age and professional occupation; duration and 
etiology of the pain; associated pathologies and usual medication was collected. 
iii. Statistical analysis 
The analysis was mainly descriptive using the means and standard deviations (SD) for 
continuous variables, which had all a normal distribution; and categorical variables were 
expressed as frequency distributions and percentages for the pertinent subject groups. All 
tests were applied with a 95% confidence interval (ρ < 0.05): ρ<0.05 is considered 
significant, 0.001<ρ< 0.01 very significant, and ρ<0.001 extremely significant.   
Accordingly Bouhassira et al. (2013), pain intensity scores of 1 to 3 were an indicative of 
mild pain, scores of 4 to 6 were an indicative of moderate pain, and scores of 7 to 10 
indicate severe pain. 
The data analysis was performed using Statistical Package for the Social Sciences version 
22 software and Microsoft Excel. 
The Chi-Square test of independence was applied to nominal variables to see whether the 
proportions of one variable are different for different values of the other variable.  
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The independent-samples t-test was applied to compare the means between two unrelated 
groups on the same continuous, dependent variable. 
Results 
A total of 84 patients reported having pain. The data were collected in four seasons: (i) 
summer, n=29; (ii) autumn, n=16; (iii) winter, n=18 and (iv) spring, n=21.  
Table VI shows the main socio-demographic characteristics, the description of pain 
duration, associated comorbidities and the use of medication in the studied patients. The 
patients mean age was 63±15.5 years old, 82% were women, had pain for more than 3 
months, indicated often more than one associated comorbidity and use of medication 
regularly. Despite the majority of the patients were retired, there is a predominance of 
active individuals (50%) in autumn. 
 
Table VI: Main socio-demographic characteristics of the sample, the description of pain duration and the 
use of medication. 
  Summer Autumn Winter Spring 
N 29 16 18 21 
Mean age±SD (years old) 64±17 63±17 63±13 62±15 
Gender (%) 
Female 72 88 83 86 
Male 28 13 17 14 
Occupation 
(%) 
Active 28 50 17 33 
Unemployed 3 6 11 5 
Retired 69 44 72 62 
Pain duration 
(%) 
Occasional 0 0 0 19 
< 3 months 10 0 17 14 
> 3 months 90 100 83 67 
Other 
comorbidities 
(%) 
Hypertension 24 19 39 33 
Diabetes 21 13 6 24 
Hypercholesterolemia 28 13 44 38 
Medication 
(%) 
No medication 10 6 11 10 
Medication 90 94 89 90 
 
SD – Standard Deviation 
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The prevalence of CP in the population studied, considering the minimum of pain 
duration of 3 months, is 85 % (n=71); 10 % (n=9) for less than 3 months and 5% (n=4) 
indicated that the pain was occasional.  
The most frequent pain locations are presented in Graphic I, standing out the lumbar, hip, 
thigh and leg locations, with the highest peaks on autumn (44% and 63%, respectively),  
and shoulder, arm and forearm that are transversal to 3 seasons (summer and autumn – 
31% each and spring – 33%). It is verified that exist an association between the pain 
location - foot and ankle and seasons (ρ=0.018).  
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Graphic I: Most frequent pain locations. 
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The usual patient’s medication is diverse, nevertheless, it is possible to verify that the 
nonsteroidal anti-inflammatory drugs (NSAIDs) and the lipid lowering agents 
consumption are highlighted (Graphic II). NSAIDs have the major percentage of intake 
on autumn (63%). 
 
  
Graphic II: Most used medication distribution. 
 
Concerning BPI results, autumn is the season in which the patients declared to have more 
pain, referring to the minimal pain in previous week with a score of 4±2 (0-10  pain scale). 
Concerning the maximum pain felt in previous week, summer and autumn reached the 
highest scores (7±2), that is considered severe pain. The highest score (5±3) for the pain 
at the time of the interview was obtained in spring (Graphic III). All diabetic patients 
(15% of study population) had a maximum score of pain in the previous week greater 
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than 5 (0-10 pain scale), and 54% of those had scores above 8, which indicates presence 
of moderate to severe pain. 
 
 
Graphic III: Description of pain in the previous week and at the time (BPI). 
 
Regarding pain relief by medication evaluated with BPI, winter was the season where 
patients indicated a higher pain relief (65%), followed by spring (61%), autumn (59%) 
and summer (42%). The pharmacotherapeutic groups commonly used for pain relief are 
presented on Graphic IV. As above mentioned in the usual medication, the NSAIDs group 
stands out also as usual medication for pain, with highest percentages of consumption in 
spring and autumn (52% and 50%, respectively). Other pharmacotherapeutic groups 
appear as pain drugs, as analgesics and antipyretics (21%, seasons mean) and muscle 
relaxants (5%, seasons mean). 
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Graphic IV: Specific pain medication (BPI). 
 
Through BPI application is possible to describe the pain interference on patient’s daily 
activities (Graphic V). In almost every daily tasks (sleep, walking ability and general 
activity), the season with the highest scores is autumn. Concerning the less affected daily 
task, the patients had affirmed that it is the relation with other people (2.5±3.3). The 
normal working is the daily task equally affected through the seasons (5.0±3.8).  
 
 
Graphic V: Pain interference on patients’ daily activities (BPI). 
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Analyzing the results of DN4 questionnaire (Graphic VI), the most common neuropathic 
complaints are brushing (71% in spring), hypoesthesia to prick (62% in spring), pins and 
needles (56% in autumn) and tingling (43% in spring). The spring is the season with the 
highest percentages of neuropathic complaints, contrary to summer that has the lowest 
values. It was verified an association between itching complaints and seasons (ρ=0.016). 
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Graphic VI: Most common pain complaints (DN4).   
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A total of 39 participants (46%) had NP as determined by a DN4 score > 4. The average 
score on the DN4 questionnaire for patients with non-neuropathic pain (NNP) was 
1.4±1.1 and 5.5±1.3 in the patients with NP. Relating neuropathic patients and diabetes, 
it was found 6 participants (7%) that may have diabetic neuropathy (DN). 
Patients with NNP and NP have similar features (Table VII), concerning season, age, sex, 
occupation, presence of other comorbidities and pain duration, no  statistical significance 
was found since p value was always higher than 0.05. Having hypertension (44% of NP 
patients), being female (87% of NP patients) and being retired (54% of NP patients) are 
some factors that may be associated to the presence of NP but with no statistical 
significance. Concerning the DN4 items, NP patients presented higher scores for DN4 
survey than NNP (ρ<0.05), showing an association between NP and most usual pain 
complaints. 
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Table VII: Socio-demographic characteristics and neuropathic complaints evaluation in patients with 
neuropathic and non-neuropathic pain. 
 NNP (n=45) NP ( n=39) ρ value 
Season, Su/Au/Wi/Sp (%) 42/20/22/16 26/18/21/36 0.158 
Mean age ± SD (years old) 64±16 61±14 0.345 
Sex, M/F (%) 24/76 13/87 0.283 
Occupation, A/U/R (%) 22/7/71 38/8/54 0.231 
Other comorbidities    
  Hypertension, Y/N (%) 22/78 44/56 0.063 
  Diabetes, Y/N (%) 16/84 15/85 0.983 
  Hypercholesterolemia, Y/N (%) 31/69 33/67 0.828 
Pain Duration, O/A/C (%) 4/13/82 5/8/87 0.808 
DN4 items, Y/N (%)    
  Burning 4/96 43/56 0.000*** 
  Painful cold 7/93 33/67 0.005** 
  Electric shocks 11/89 33/67 0.027* 
  Tingling 18/82 54/46 0.001** 
  Pins and needles 20/80 62/38 0.000*** 
  Numbness 11/89 59/41 0.000*** 
  Itching 9/91 33/67 0.012* 
  Hypoesthesia to touch 13/87 64/36 0.000*** 
  Hypoesthesia to prick 9/91 74/26 0.000*** 
  Brushing 40/60 97/3 0.000*** 
NNP – Non Neuropathic Pain; NP – Neuropathic Pain; Su – Summer; Au – Autumn; Wi – Winter; Sp – Spring; M – 
Male; F – Female; A – Active; U – Unemployed; R – Retired; HT – Hypertension; D – Diabetes; HC – 
Hypercholesterolemia; Y – Yes; N – No; O – Occasional; A – Acute ( < 3  months); C – Chronic ( > 3months); * 
ρ<0.05; **0.001 <ρ< 0.01; *** ρ<0.001 
 
Diabetic patients with NNP were older (ρ=0.018) than with NP (Table VIII). Being retired 
is more prevalent in diabetic non-neuropathic pain (DNNP) patients than in diabetic 
neuropathic pain (DNP) patients. Concerning the DN4 items, DNP patients presented 
more elevated scores for DN4 items, hypoesthesia to prick and brushing than DNNP 
(ρ=0.021 and ρ=0.005, respectively), showing an association between DNP and the this two 
pain complaints (DN4). The other results for DN4 evaluation did not presented any 
statistical difference and are not shown. 
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Table VIII: Socio-demographic characteristics and neuropathic complaints evaluation in diabetic patients 
with neuropathic and non-neuropathic pain.  
 DNNP (n=7) DNP  (n=6) ρ value 
Mean age ± SD (years old) 74±6 62±10 0.018* 
Sex, M/F (%) 43/57 17/83 0.559 
Occupation, A/R (%) 0/100 50/50 0.077 
Pain Duration, O/A/C (%) 0/0/100 11/11/78 1.000 
DN4 items, Y/N (%)    
  Hypoesthesia to prick 0/100 67/33 0.021* 
  Brushing 14/86 100/0 0.005** 
DNNP – Diabetic Non-Neuropathic Pain; DNP – Diabetic Neuropathic Pain; M – Male; F – Female; A – Active; U – 
Unemployed; R – Retired; HT – Hypertension; D – Diabetes; HC – Hypercholesterolemia; O – Occasional; A – Acute 
( < 3  months); C – Chronic ( > 3months); * ρ < 0.05; **0.001 < ρ < 0.01 
 
Through the analysis of table IX, neuropathic patients with or without diabetes have 
identical characteristics. For BPI and DN4 results no statistical significance was found 
since p value was always higher than 0.05. All of the DNP patients referred presence of 
pain with brushing and presented a maximum score of pain in the previous week higher 
than 5 (0-10 pain scale) in BPI, that indicates moderate to severe pain.  
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Table IX: Frequency of positive items in non-diabetic neuropathic and diabetic neuropathic patients. 
 NDNP (n=33) DNP (n=6) ρ value 
Season, Su/A/W/Sp (%) 21/21/21/36 50/0/17/33 0.395 
BPI mean > 5 (%) 67 50 0.647 
BPI > 5 (%) 88 100 1.000 
DN4 items (%)    
  Burning 45 33 0.679 
  Painful cold 33 33 1.000 
  Electric shocks 36 17 0.643 
  Tingling 52 67 0.667 
  Pins and needles 61 67 1.000 
  Numbness 58 83 0.370 
  Itching 27 67 0.153 
  Hypoesthesia to touch 61 67 1.000 
  Hypoesthesia to prick 79 67 0.636 
  Brushing 94 100 1.000 
NDNP – Non-Diabetic Neuropathic Pain; DNP – Diabetic Neuropathic Pain; Su – Summer; Au – Autumn; Wi – Winter; 
Sp – Spring; BPI – Brief Pain Inventory; DN4 – Douleur neuropathique 4 
 
Discussion/Conclusion 
The management of CP, in order to improve pain patient’s healthcare and decrease the 
associated social burden, is urgent. Thus, the full knowledge of the characteristics of pain 
becomes crucial. 
To our knowledge no study has previously been conducted for chronic and NP in Portugal 
comprising data from the four seasons. 
 It is notable that CP, especially NP, has a huge impact in daily activities resulting in an 
impairment of QoL.  
Our data indicate that being female and increasing age are some of the factors associated 
with CP and NP. These factors are also presented by several studies and are in accordance 
with the common demographic profile of CP (L. F. Azevedo et al., 2012; Bouhassira et 
al., 2008; Breivik et al., 2013; Cortez et al., 2014; De Moraes Vieira et al., 2012; Dieleman 
et al., 2008; Harifi et al., 2013; Kasim, Amar, Sadek, & Gawad, 2010; Lekpa et al., 2013; 
Reid et al., 2011; Timmerman, Wilder-Smith, van Weel, Wolff, & Vissers, 2014; 
Torrance et al., 2006). 
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The subjects presenting NNP are older than those in the NP group, even though the 
differences in all variables (season, gender, occupation, comorbidities and pain duration) 
were not statistically significant. According to Langley and colleagues (2013), the NP 
patients were older than the control group but the other variables are in agreement with 
our study. Breivik and collaborators (2013) identified that manual workers and the 
unemployed individuals are more likely to have CP instead of professional workers, but, 
in a Portuguese study, and in accordance with our data, the retired individuals is the group 
with more prevalence of CP (L. F. Azevedo et al., 2012). This discrepancy may be 
explained by the increase age of the participants in the Portuguese study and in our own. 
Also, in autumn it was noticed a prevalence of active individuals in contrast with other 
three seasons. This may be explicated since our sample for this season, in particularly, 
presented more individuals with active occupation than other season.  
In this study, the criterion to consider the presence of CP was reporting pain for more 
than 3 months, thus CP is present in 85 % of the studied population. This results represents 
an increased percentage compared with previous studies in Portugal which reported only 
37% (L. F. Azevedo et al., 2012). This fact may be explained by the low number of the 
participants (n=84) and by the target population (only participants with pain complaints), 
which do not fully represents the entire population. Yet, there is noticed an increase in 
the prevalence of CP globally (Chang et al., 2015). 
The most frequent pain locations were the lumbar, hip, thigh and leg, and shoulder, arm 
and forearm in agreement with results already published (P C Langley, 2011; Reid et al., 
2011; Timmerman et al., 2014). 
NSAIDs and lipid lowering agents are the medicines with major consumption within 
usual patients medication which could be justified by the higher percentage of patients 
with CP and hypercholesterolemia (31%), respectively.  
Concerning BPI results, the average maximum pain and the average pain in previous 
week were 6.5±2 and 5.3±2 (0-10  pain scale), respectively, which may be considered 
moderate to severe pain which is in agreement with several published studies (L. F. 
Azevedo et al., 2012; Bouhassira et al., 2013; P C Langley, 2011).  
A pain increase has a great impact in the QoL of the patients and often interferes with 
almost all daily duties, such as family and home tasks, entertaining activities (i.e. 
exercise) and sleep (Baker et al., 2010; Breivik et al., 2013; Reid et al., 2011; Votrubec 
& Thong, 2013). 
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All of diabetic patients presented a maximum score of pain in the previous week regarded 
as moderate to severe, as well ½ of diabetic patients reached a score above 8 (0-10  pain 
scale). Over the time, CP has been associated with other comorbidities, and several factors 
are pointed as significantly associated with an increased risk of neuropathy occurrence: 
the diabetes duration, poor control of diabetes and associated hypertension, among others.  
Diabetes up rises as one of the most affected conditions, where the nerve tissues are in a 
proinflammatory state which is a major cause in the progress of DN, and consequently 
impacting dramatically the QoL (Barbosa et al., 2014; Chang et al., 2015; Freeman, 2013; 
Hosseini & Abdollahi, 2013; Kasim et al., 2010; Kumar et al., 2012; Lapane et al., 2014; 
Liberman et al., 2014; Nenke et al., 2015; Wang et al., 2014). 
The pain treatment is a challenging task, even today with the existence of numerous 
medicines for its treatment. Currently, many patients are unsatisfied with their 
pharmacological therapy which does not provide reasonable pain relief. This permits the 
development of new non-pharmacological therapies, less harmful, that could improve 
significantly the QoL. Our patients indicated 57% in pain relief when they use medicines 
specific for pain. Once more, and in accordance with several studies, the NSAIDs group 
highlights as usual medication for pain. Other drugs were emphasized, the analgesics and 
antipyretics and the muscle relaxants (Baker et al., 2010; De Andrés et al., 2014; Freeman, 
2013; Jouini et al., 2014; Lapane et al., 2014; Reid et al., 2011). Reid and colleagues 
(2011) pointed the use of antidepressants (28.7%) and antiepileptics (51%) as non-
standard pain medication but in our population the consumption of these drugs was lower, 
7% each. Although many NP patients are regularly medicated with NSAIDs, this group 
of drugs has more beneficial effects in the treatment of nociceptive pain than NP (Cecil, 
Goldman, & Schafer, 2012).  The highest percentages of NSAIDs consumption were in 
spring and autumn in accordance with the highest peaks of pain complaints in both groups 
(NP and NNP). 
Lapane and colleagues (2014) concluded that pain intensity is significantly related with 
diminishing of both physical and mental health components of QoL. Other study refers, 
in agreement with the previous study and ours, that patients with CP have a reduction in 
health-related QoL and psychological welfare (Moulin et al., 2015). 
Distinguishing neuropathic from nociceptive pain is challenging, thus several instruments 
were created and standardized with this purpose (Barbosa et al., 2014). DN4, among 
others, is a useful tool for the evaluation of neuropathic characteristics once NP is 
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typically described as burning, painful, cold or electric shocks and may be associated with 
tingling, pins and needles, and numbness or itching (Votrubec & Thong, 2013). However, 
the questionnaires cannot access all the pain specificities and, therefore, the DN4 should 
not replace a clinical evaluation which provides more specific indications about the pain 
and its causes. (Mathieson et al., 2015). Almost 50 % of participants in our study had NP 
as determined by a DN4 score > 4. One of the largest studies realized in Europe indicates 
that one in five of diabetic patients suffer pain in a daily-based approach, often associated 
with neuropathic features. (Bouhassira et al., 2013). And other study, indicates that  63 % 
of the patients evaluated  had a NP component (Hamdan et al., 2014). The most common 
neuropathic complaints are brushing, hypoesthesia to prick, pins and needles and tingling.  
Comparing NP patients with NNP, it was verified an enormous association between NP 
and NP complaints. All NP pain complaints were significantly increased in NP patients, 
which was expected since these complaints are characteristic of this type of pain. 
Calcutt, in his study, stated that a percentage of people with diabetes also reports 
spontaneous tingling, pricking, and pain sensations (Calcutt, 2013). In agreement with 
Lepka and collaborators (2013), our study presents musculoskeletal pain as the main 
complaint of patients with DN. Even though DN is often underdiagnosed, less than 1/3 
of physicians recognize the cause or discuss this with their patients. This needs to be 
improved and the physicians must be sensitized for the theme (Vinik, Nevoret, Casellini, 
& Parson, 2013). 
It was verified a significant association between diabetic patients with neuropathic pain 
and two typical neuropathic pain complaints, hypoesthesia to prick and brushing. It is 
know that a diabetic state may influence the pain perception, boosting it. This may be 
explained for the different sensitive pathways. Tactile sensation is divided into (i) crude 
touch, where the thicker fibers spread impulses such as those arising in touch receptors, 
and (ii) fine touch, where the thinner fibers, transmit slower transmission, leading to pain 
impulses (Klaumann, Wouk, & Sillas, 2008; Patestas & Gartner, 2009).  
It is known that weather conditions may negatively influence the pain (Smedslund & 
Hagen, 2011). However there are several potential factors, such as low mood, poor sleep 
quality and lack of exercise, which may interfere in the relation between weather and pain 
complaints (Macfarlane, McBeth, Jones, Nicholl, & Macfarlane, 2010). On the other 
hand, meteorological factors, such as barometric pressure, humidity, and temperature, 
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have been matter of study due to their capability of influence CP. (Cunha Miranda et al., 
2007; Funakubo, Sato, Obata, & Mizumura, 2011). 
According to several studies, the prevalence of any kind of pain is elevated during the 
seasons with less sunlight and lower temperatures (autumn and winter, in Northern 
Hemisphere), and suffers a decrease in summer (Breivik, 2010; Macfarlane et al., 2010; 
Saps et al., 2013; Erik J Timmermans et al., 2014). But, it is not a consensus subject 
(McAlindon, Formica, Schmid, & Fletcher, 2007).  A study about the influence of 
humidity on pain suggested that pain was higher in cold meteorological conditions due to 
the increasing of viscosity of synovial fluid (E. J. Timmermans et al., 2015). Our study 
reports pain complaints increased during autumn and summer, with a score of 7 (BPI 0-
10 pain scale) in the maximum pain on the previous week. And for pain with neuropathic 
features, the spring is the season with the highest percentages, contrary to summer, that 
presented the lowest values. This is not completely in agreement with the published 
studies, but, as we know, the weather influence is partially explained by mood and 
behavior fluctuations, and all of our subjects reported mild to severe pain, being, therefore 
susceptible (Macfarlane et al., 2010; Erik J Timmermans et al., 2014). Concerning the 
itching complaint as being significantly associated to the seasons, it was verified elevated 
complaints on winter, which could be explained for vasoconstriction phenomena that may 
lead to an increase of pain perception (Mathias & Bannister, 2013). After all, this 
discrepancy may be explained due to the diversity of pain components, which are difficult 
to study in a closed environment (Cunha Miranda et al., 2007).   
This study has some limitations: (i) it is based on a convenience sample which does not 
accurately represent the general population and may under or overestimate population 
values; (ii) the questionnaires were applied directly in target population, and were based 
only in the description of pain experienced by the respondents; (iii) it was not assured a 
clinical confirmation of the presence of pain, pain conditions reported, and the presence 
of comorbidities. 
In order to confirm our results, it is desirable to perform additional studies with larger 
community-based data which will permit the comparison between the characteristics and 
the experience of NP patients with other CP conditions. 
In conclusion, our results suggest that being a female, the increased age and being retired 
can influence CP and NP in several patients. The scores obtained in BPI indicate the 
presence of moderate to severe pain, with implications in almost daily activities. The DN4 
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indicated the presence of nearly 50% of patients with NP. Thus, CP associated or not with 
NP is perhaps more predominant in the population than was formerly assumed and 
normally is characterized as more severe than other CP conditions. Consequently pain 
evaluation is helpful and with a great importance, as well as the self-management 
approaches, because of their impact in the improvement of QoL. 
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General discussion and conclusion  
Through the meta-analysis and the data collection about pain complaints and its 
characteristics, it was possible to analyze and relate the major actors in the development 
of diabetic neuropathy (DN): diabetes, chronic pain and oxidative stress (OS). 
OS may be a leading cause for progress and aggravation of DN. The meta-analysis and 
systematic review contributed to the understanding of OS role and importance in patients 
with DN, as well as to establish several OS biomarkers with potential for the use in 
diagnose, such as lipid peroxidation, superoxide dismutase, catalase and reduced 
glutathione. These OS biomarkers allow a more effective accompaniment of the OS status 
of diabetic neuropathic patients, supporting a better and more accurate treatment. 
The application of Brief Pain Inventory and Douleur Neuropathique 4 was accomplished 
in a convenience sample, which included patients of a medical clinic that agreed to 
participate in the study. The data analysis, resultant from the two surveys application, 
permitted the achievement of more insight in the prevalence, severity, and treatment of 
neuropathic symptoms in patients with moderate to severe pain and its interference with 
daily activities. Our results indicated that a large number of people have daily pain 
complaints, even under medication, and a high percentage of them presented neuropathic 
pain characteristics. Concerning the usual pain medication (NSAIDs), it was possible 
verify that it is unappropriated to treat effectively neuropathic pain, since is more 
indicated in treatment of nociceptive pain. 
The data collection across the four seasons potentiated the current believing that climate 
alterations and meteorological conditions influence the pain complaints. 
Pain arises as a major issue in their daily routines, which has a great impact in QoL. 
Hence, our results reinforce the importance of pain diagnostic and treatment, among 
patients, caregivers and medical class. 
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Future perspectives  
As future perspectives we aim to study the influence of infection on processes of the 
nervous system, including neurodegenerative diseases and pain pathways, particularly in 
the modulation of the oxidative/inflammatory environment. 
Through the use of bacterial infection/inflammation models, with bacterial strains that are 
sensitive and resistant to antimicrobial agents, we intend to study their influence on 
pathological processes of nervous system (i.e. Parkinson's and Alzheimer's diseases). 
Additionally, to extend these studies to other pathological processes in the nervous 
system, as the processes underlying the development of chronic pain. We intend to 
evaluate, through analytical techniques, molecular players, specifically associated to 
oxidative stress and inflammation, involved in pathologic pathways and to characterize 
their relation. This evaluation will be carried out using biological models already used at 
the nervous system level, such as Caenorhabditis elegans, among others, and by 
developing new models and methodologies. The characterization of the potential 
connection between infection/inflammation and nervous system pathological processes, 
with high prevalence and impact on Public Health, such as neurodegenerative processes 
or development of chronic pain, will be extremely relevant. The obtained data may allow 
early intervention for improving the diagnosis, and also a more timely therapeutic 
intervention, with great impact on disease pathogenesis, and high gains in health and 
quality of life. 
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Appendix I – scientific communications in poster 
 
Title: Oxidative Stress in Diabetic Neuropathy 
 
 
Poster abstract submitted and accepted at IV Congresso de Cuidados Paliativos – IPO, 
Portugal 2014. 
 
Introduction 
Diabetes is an epidemic disease, considered a public health major issue and also in 
Palliative Care. Diabetic neuropathy (DN) is defined as a demonstrable disorder, either 
clinically evident or subclinical, that occurs in setting of diabetes without other causes for 
peripheral neuropathy. Oxidative stress (OS) is related to several physiological and 
pathological processes and there are several evidence pointing to its involvement in DN. 
Objectives 
To review the evidences about the relation between OS and DN in order to contribute to 
the overall understanding of the mechanisms involved.  
Material and methods 
The keywords used for the search were diabetes, DN, OS, reactive oxygen species and 
glutathione. Science Direct and PubMed databases were used. 
Results 
The research made point that the key factor in the progress of DN is the generation of free 
radicals by amplified glycolytic processes. An excess of blood glucose leads to an 
overload of electron transport chain and, therefore, to the production of superoxide 
species. Subsequently mitochondrial and cytosolic OS are generated. Also there are 
evidence that the beginning of diabetes may be deeply connected with OS. 
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Discussion/Conclusion 
In diabetes, the mitochondrial metabolism and the cascade of oxidative phosphorylation 
are pointed as significant contributors of ROS generation that are present and increased 
in both T1D and T2D conditions. This increased production seems to be caused by 
hyperglycemia. These results contribute to the elucidation of the relation between OS and 
DN and thus may better allow earlier and better diagnosis and new and optimized 
treatment. 
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Title: Study of Duration and Etiology of Pain, Associated Pathologies and Usual 
Medication in Patients Attending Clínica Médica Povo Portuense 
 
 
Poster abstract submitted and accepted at IV Congresso de Cuidados Paliativos - IPO, 
Portugal 2014. 
 
Introduction 
Pain has great impact in quality of life and other associated pathologies and is of great 
importance in palliative care. Thus the study of its main characteristics contributes to 
better care. 
Objectives 
To assess the duration and etiology of the pain, the associated pathologies and usual 
medication as well as to study its socio-demographic characteristics. 
Material and methods 
A convenience sample (n=32) of patients of Clínica Médica Povo Portuense voluntarily 
and by personal contact agreed to participate in this study. The parameters assessed were 
socio-demographic characterization including gender, age and professional occupation, 
the duration and etiology of the pain, the associated pathologies and usual medication. 
An informed consent was sign. 
Results 
The results were obtained on a sample composed of 24 % males and 76 % females with 
a mean age of 62 years. Analyzing the pain results, 95% of the respondents have pain for 
more than 3 months (CP) and 76 % have pain in more than one location. 43% have 
identified lumbar spine, shoulder, arm and forearm as the more frequent pain location, 
followed by cervical spine, hip, thigh and leg (29%).Only 19 % declared no other 
pathologies. 29% indicates more than 2 pathologies, namely diabetes, hypertension and 
hypercholesterolemia. 10 % refers all the three pathologies diagnosed.  
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Discussion/Conclusion 
Our results indicate an association between age and pain complaints. It was also possible 
to identify the duration and etiology of the pain and to verify that pain complaints seem 
to be related with other pathologies. 
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Title: Main Characteristics of Pain in Patients Attending Clínica Médica Povo 
Portuense Assessed by Brief Pain Inventory and by Douleur Neuropathique 4 
 
 
 
Poster abstract submitted and accepted at IV Congresso de Cuidados Paliativos - IPO, 
Portugal 2014. 
 
Introduction 
Chronic pain is multifactorial and needs correct assessment to distinguish their 
components with implications in treatment. Thus in the study of pain, neuropathic pain 
(NP) must be assessed. 
Objectives 
To characterize pain: local, intensity, impact, relief by medication and its effect on daily 
activities, using Brief Pain Inventory (BPI).  
To determine the main features associated with NP, using Douleur Neuropathique 4 
(DN4). 
Material and methods 
A convenience sample (n=32) of patients of Clínica Médica Povo Portuense voluntarily 
and by personal contact agreed to participate in this study. Portuguese validated versions 
of two surveys were applied: BPI and DN4. An informed consent was signed. 
Results 
The results (BPI) indicate that 40 % of patients using pain medication have relief 
symptoms. The mean score for maximum pain in previous week was 7±2 and the 
minimum was 2±2 in a scale 0-10. General activity, mood and daily work were pointed 
as the most influenced by the pain. The relationship with others and the pleasure of living 
were the less influenced by the pain. 1/3 of the sample has NP (DN4). 62 % indicated 
pain when brushing and also tingling (43 %) and numbness (38 %) are pointed. 
Oxidative Stress in Diabetic Neuropathy 
86 
 
Discussion/Conclusion 
The maximum pain felt by the patients in the week before survey was very high (7 in 10). 
Results indicate that pain interferes in several essential tasks. Medication seems not 
completely effective. An expressive 1/3 of patients seem to have NP. These results further 
reinforce the need for attention on pain diagnostic and treatment. 
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Appendix II – oral communication 
 
Oral communication abstract submitted and accepted at II Congresso Internacional da 
Saúde Gaia-Porto, Porto, Portugal 2015 and present in congress proceedings (waiting for 
ISBN)  
 
Title: Assessment of Pain Characteristics in Patients of Clínica Médica Povo 
Portuense: 3 Seasons Study 
 
 
Authors 
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Introduction 
Currently, most of the patients having chronic pain (CP) present neuropathic pain (NP). 
Therefore, the study of the main features of pain contributes to a better and more 
appropriate treatment 
Objectives 
To study the duration and etiology of pain, associated pathologies (AP) and usual 
medication (UM) as well its socio-demographic characteristics (SDC). To assess pain 
location (PL), intensity, relief by medication and its effect on daily activities (DA). To 
determine the main features of NP. 
Materials and Methods 
Data collection was made over 3 seasons: n=63. The convenience sample was CMPP 
patients that voluntarily and by personal contact agreed to participate in this study, signing 
an informed consent. The parameters assessed were SCD (gender, age and occupation), 
pain duration (PD) and pain etiology, AP and UM. Two surveys were applied: Brief Pain 
Inventory (BPI) and Douleur Neuropathique 4(DN4). This study was approved by ESTSP 
Ethics Commission. 
Results and Discussion 
Patients mean age was 63years, mostly females (82%), and 63% were retired. The PD is 
longer than 3months and is transverse to the 3seasons (91%). 49% have identified hip, 
thigh and leg, and 36% lumbar as the more frequent PL. Concerning AP, patients with 
hypertension, hypercholesterolemia and diabetes were found. 91% of the patients 
indicated use of pain medication(PM). The mean score in the 3seasons for maximum pain 
was 7±2 (scale 0-10). The most influenced DA were general activity, normal work and 
sleep (8, scale 0-10). The results indicate that 57% of patients using PM have relief 
symptoms. Brushing was the higher complaint (64%). 
Conclusion 
This study enables crossing data over 3seasons, where the age seems to be related to pain 
complaints (PC). Our results indicate that autumn is the season with more PC, having a 
higher consumption of PM. Presumable NP is present in 44% of population. These results 
suggest that DA are affected by pain, and medication does not look totally effective. 
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Appendix III – Applied surveys 
i. Informed consent 
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ii. Brief Pain Inventory 
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iii. Douleur Neuropathique 4 
 
